Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations

NCT01410214 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer Stage IIIA

Interventions

DRUG: Erlotinib
DRUG: vinorelbine/cisplatin

Sponsor

Chinese Lung Cancer Surgical Group

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]